bêta
IA Trial Radar
L'essai clinique NCT06349941 pour Insuffisance cardiaque est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte

Home-based Cardiac Rehabilitation in Heart Failure

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'essai clinique NCT06349941 est conçu pour étudier le treatment de Insuffisance cardiaque. Il s'agit d'un essai interventionnel en Phase III. Son statut actuel est : en recrutement. L'essai a débuté le 15 août 2025 et vise à recruter 332 participants. Dirigé par le Centre médical du Sud-Ouest de l'Université du Texas, l'essai devrait être terminé d'ici le 1 décembre 2028. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 21 août 2025.
Résumé succinct
This study evaluates a mobile health (mHealth) home-based cardiac rehabilitation program for patients with heart failure. We will stratify randomization between rural and urban populations, with the goal to assess implementation of cardiac rehabilitation across these two geographic areas. . The study will randomize 332 patients with heart failure (ejection fraction ≥35%) who are not eligible for center-based rehabilitation to either a 12-week mHealth cardiac rehabilitation program or an attention control group, with outcomes measured over 6 months using a composite endpoint of mortality, hospitalizations, and quality of life. We will then assess the implementation of the intervention.
Description détaillée
Background and Significance:

Rural communities in the United States experience a disproportionate burden of cardiovascular disease and associated adverse outcomes, with recent epidemiological data demonstrating a widening mortality gap compared to urban populations. These disparities are particularly pronounced in cardiovascular care delivery, where rural-residing adults demonstrate significantly lower rates of guideline-directed therapies for coronary heart disease, heart failure, and stroke. Among the most substantial gaps identified is the utilization of cardiac rehabilitation services, with total participation among Medicare beneficiaries reaching only 5% in rural areas. This disparity is compounded by the intersection of multiple risk factors including reduced access to healthcare services, lower socioeconomic status, and geographic barriers to specialized care.

The emergence of telemedicine platforms presents a novel opportunity to address these healthcare access disparities through innovative service delivery models. The COVID-19 pandemic has catalyzed the adoption of digital health technologies, with telemedicine visits among rural Medicare beneficiaries increasing nearly 100-fold between 2019 and 2020. Concurrent improvements in rural broadband access, with over 70% of rural adults reporting home broadband availability in 2021, have created an infrastructure foundation supporting telehealth interventions. Mobile health (mHealth) interventions have demonstrated efficacy in cardiovascular care through patient monitoring, medication adherence support, and risk factor management, with preliminary evidence suggesting effectiveness in reducing rehospitalizations and increasing patient participation in cardiac rehabilitation programs.

Study Design and Methodology:

This investigation employs a randomized, open-label, Type 1 hybrid effectiveness-implementation trial design to evaluate the efficacy and implementation characteristics of an mHealth-enabled home-based cardiac rehabilitation program. The study will enroll 332 adult participants with recent hospitalization for heart failure with ejection fraction ≥35%, stratified with 70% recruitment from rural hospitals and 30% from urban centers to enable comparative analysis of implementation challenges across geographic settings. Participants will be randomized in a 1:1 ratio to receive either the mHealth cardiac rehabilitation intervention or attention control, with outcomes assessed over a 6-month follow-up period.

Intervention Components:

Participants randomized to the mHealth cardiac rehabilitation group receive a comprehensive remote monitoring kit delivered via overnight shipping, containing a wireless blood pressure monitor, resistance bands, and a wearable monitor. These hardware components integrate with the Movn Health platform, which participants access through a smartphone application offering both synchronous and asynchronous features including real-time video consultations with exercise coaches, exercise videos for self-directed sessions, one-to-one messaging capabilities, and automatic data synchronization from all monitoring devices.

The 12-week cardiac rehabilitation program implements a multi-domain physical rehabilitation approach. The intervention begins with a comprehensive assessment evaluating exercise capacity and safety requirements. Each participant follows a personalized exercise regimen.

Participants in the attention control group receive a FitBit device for activity monitoring and step count tracking, along with bi-weekly telephone calls throughout the 12-week intervention period to minimize contact differential between study arms. These telephone interactions focus on general health discussions without providing specific exercise counseling or rehabilitation guidance.

Outcome Measures and Assessment:

The primary endpoint employs a composite hierarchical outcome structure analyzed using a win-ratio methodology, incorporating all-cause mortality, time to first heart failure hospitalization, total heart failure hospitalizations, and a 5-point difference in quality of life assessed by the Kansas City Cardiomyopathy Questionnaire. This analytical approach provides a comprehensive evaluation of intervention effectiveness across multiple clinically relevant domains while accounting for the relative importance of mortality and morbidity outcomes.

Secondary endpoints include individual components of the primary composite outcome, physical activity levels measured through FitBit-recorded daily step counts, and general health-related quality of life assessed using the EuroQol 5 Dimension 5 Level instrument. Additional secondary measures encompass mental health parameters evaluated through the Patient Health Questionnaire-9, Generalized Anxiety Disorder-7 scale, and the Physical Activity Scale for the Elderly.

The study incorporates comprehensive implementation outcome assessment using the RE-AIM framework, evaluating Reach through the number of eligible participants receiving the intervention, Effectiveness through perceived relative advantage and observed outcomes, Adoption through adherence rates and contextual factors, Implementation through fidelity measures and cost analysis, and Maintenance through persistence and discontinuation rates. A sequential mixed-methods approach will conduct semi-structured interviews with 12 clinicians across all sites and 36 patients across study arms to evaluate acceptability, preferences, and contextual factors influencing implementation effectiveness.

Titre officiel

Implementing a Home-based Cardiac Rehabilitation Program Among Rural Patients With Heart Failure

Conditions
Insuffisance cardiaque
Autres identifiants de l'essai
  • STU-2023-0745
Numéro NCT
Date de début (réel)
2025-08-15
Dernière mise à jour publiée
2025-08-21
Date de fin (estimée)
2028-12-01
Inscription (estimée)
332
Type d'essai
Interventionnel
PHASE
Phase III
Statut
En recrutement
Mots clés
telehealth
heart failure
rural
cardiac rehabilitaion
Objectif principal
Traitement
Plan d'attribution
Randomisé
Modèle d'intervention
Parallèle
Masquage
Aucun (ouvert)
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
ExpérimentalMovn cardiac rehabilitation
Cardiac rehabilitation delivered through Movn app through the use of mHealth.
Movn APP
Participants will have 12-week home-based exercise program delivered via a commercially available home-based cardiac rehabilitation platform called Movn. The plan includes an accelerometer, blood pressure scale, and mobile application.
Comparateur actifAttention Control
This group will receive a wearable device for step count tracking and will get periodic check ins to minimize differential attention between groups. They will not receive an exercise plan.
Accéléromètre
Participants will receive a FitBit for monitoring of physical function.
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
Composite Hierarchical Endpoint
A composite outcome incorporating all-cause mortality, time to first heart failure hospitalization, total heart failure hospitalizations, and a 5-point difference in disease-specific quality of life score as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ ranges from 0-100, where 0 indicates worst quality of life and 100 indicates best quality of life.
6 months.
Critère secondaire d'évaluation
Critères d'évaluationDescription de critèresPériode
Physical Activity Level
Daily Step Count
Continuously measured over 6 months.
General Health-Related Quality of Life
Change in general health-related quality of life assessed using the EuroQol 5 Dimension 5 Level (EQ-5D-5L) instrument. The EQ-5D-5L uses a descriptive system to measure health-related quality of life across five key dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on five levels of severity-ranging from no problems (Level 1) to extreme problems or inability to function (Level 5). A respondent's answers generate a five-digit health state profile that reflects their unique combination of responses (e.g., 12345), representing one of 3,125 possible health states. This descriptive system enables consistent and standardized assessment of an individual's health status.
Baseline, 3 months, and 6 months
Implementation Outcomes
Assessment of the implementation of the cardiac rehabilitation program using mixed methods evaluation.
Assessed at 3 and 6 months.
Depressive Symptoms
Change in mental health parameters assessed using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.
Baseline, 3 months, and 6 months
Anxiety Symptoms
Change in anxiety symptoms assessed using the Generalized Anxiety Disorder-7 (GAD-7) scale. Total scores range from 0 to 21, with higher scoes indicating more severe anxiety symptoms.
Baseline, 3 months, and 6 months
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
18 Years
Sexes éligibles
Tous
  • Adults aged 18 years or older
  • History of hospitalization for acute heart failure with ejection fraction ≥ 35%
  • Ability to participate in telemedicine visits
  • Access to smartphone or device capable of running the mHealth application
  • Willingness to participate in home-based cardiac rehabilitation program

  • Heart failure with reduced ejection fraction (ejection fraction < 35%)
  • Inability to participate in physical exercise or cardiac rehabilitation due to medical contraindications
  • Inability to provide informed consent
  • Lack of access to required technology (smartphone, internet connectivity)
  • Life expectancy less than 6 months
  • Inability to participate in telemedicine visits or remote monitoring
  • Current participation in another cardiac rehabilitation program
University of Texas Southwestern Medical Center logoCentre médical du Sud-Ouest de l'Université du Texas285 essais cliniques actifs à explorer
Partie responsable de l'essai
Ambarish Pandey, Investigateur principal, Associate Professor, University of Texas Southwestern Medical Center
Aucune donnée de contact disponible
2 Centres de l'essai dans 1 pays

Texas

University of Texas Southwestern Medical Center, Dallas, Texas, 75209, United States
Ambarish Pandey, MD, Contact, 214-645-9868, [email protected]
En recrutement
Baylor Scott and White Health System, Dallas, Texas, 75246, United States
Neil Keshvani, MD, Contact, 214-384-9004, [email protected]
Pas encore en recrutement